Navigation Links
More Than Half of Patients Treated for Benign Prostatic Hyperplasia Receive Boehringer Ingelheim's Flomax as First-Line Therapy
Date:4/7/2008

e effects such as retrograde ejaculation, decreased libido, and hypotension as well as patients' belief that symptoms will go away on their own are key reasons for the low drug-treatment rate.

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithm Insight Series provide the following:

-- Summary of U.S. medical practice based on interviews with leading

experts in the field.

-- Qualitative diagnosis/referral/treatment algorithm for the United

States.

-- Drug usage by lines of therapy (1st, 2nd, 3rd line).

-- Discussion of key freeform combinations by lines of therapy.

-- Product share (class and specific compound level) within each line of

therapy (1st, 2nd, 3rd line).

-- Progression of therapy from key 1st line products.

-- Pathway to key therapies from previous therapies.

-- Qualitative analysis of two-year forecast incorporating upcoming

launches, changes in reimbursement, etc.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

78
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
5. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
8. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
9. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
10. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
11. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 3, 2015  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... a focus on protecting the microbiome, announced today that ... at the 27th Annual ROTH Conference being held on March ... in Dana Point, CA. Mr. ... at 1:00 p.m. (Pacific Time). A live webcast ...
(Date:3/3/2015)... Nev. , March 3, 2015  PDL BioPharma, ... ) today announced that the third of three shareholder ... dismissed without prejudice. On February 2, 2015, ... last September on behalf of a putative class of ... Inc., et al., No. 2:14-CV-01526-APG-NJK (D. Nev.), was voluntarily ...
(Date:3/3/2015)... 2, 2015  Phillip Sharp, Institute Professor at the Massachusetts ... of Biology and the Koch Institute for Integrative Cancer Research, ... Heritage Day , May 14, at the Chemical Heritage ... Gold Medal since it was first awarded to ... 1977 Phil Sharp gave the scientific world a new ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Shimadzu Scientific ... and present on LCMS and marijuana analysis at the ... March 8 to 12 at the Ernest N. Morial ... can stop by booth 3121 to discuss laboratory challenges ... company’s innovative, proven products help save time, money and ...
Breaking Biology Technology:Synthetic Biologics to Present at the 27th Annual ROTH Conference 2PDL BioPharma Announces Dismissal of Third and Final Shareholder Lawsuit 2Phillip Sharp to Receive 2015 Othmer Gold Medal 2Phillip Sharp to Receive 2015 Othmer Gold Medal 3Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 2Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 3
... /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc.,("Dragon Pharma" or the ... international pharmaceutical company, today announced that June 26,2008 ... Annual Stockholders Meeting., The Annual Meeting of ... Chamber of Commerce Tower, Fuhua Three Road, Shenzhen, ...
... - ImmunoVaccine Technologies Inc. (IVT), a,vaccine development company, ... of Pennsylvania,s Best 50 Women in Business. Dr. ... the honors,from Pennsylvania Governor Edward G. Rendell., ... Her clinical work in,antigen discovery for ovarian and ...
... Pa., May 23 BioTrends Research Group, ... providing insight,into the referral patterns and co-management ... the perspective of Nephrologists,Cardiologists, Endocrinologists, and Primary ... a comprehensive view, based on,qualitative interviews with ...
Cached Biology Technology:ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PA's Best 50 Women in Business 2Nephrologists and Non-Nephrologists Alike Report Increased Attention on Chronic Kidney Disease 2
(Date:2/10/2015)... -- Alere Inc. (NYSE: ALR), a global leader in ... quarter ended December 31, 2014. Namal ... said, "We made substantial progress in the fourth ... in rapid diagnostics and delivering against our financial ... early January enabled us to substantially reduce our ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
(Date:2/5/2015)... Calif. , Jan. 27, 2015 /PRNewswire/ ... provider of globally deployed, innovative test solutions ... announced the delivery of its TS-323 ... Space Systems Company (LMSSC). GENASYS is a ... demands of mission-critical applications that require performance ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... those used for HIV patients may be the best way of ... Leeds. A study of a protein called p7, has revealed ... virus strains - known as genotypes - alter the sensitivity ... The p7 protein assists the spread of HCV around the ...
... Energy Joint Genome Institute (DOE JGI) has released a ... code, making it widely available to the research community ... world,s most valuable plant commodities. Soybean not only ... but also is an emerging feedstock for biodiesel production. ...
... 2008 Animal feeding operations are an important emission ... dioxideknown greenhouse gases. Recent inventories suggest that animal ... emissions. As a consequence, greenhouse gas emissions can ... and sustainability of animal production and technologies are ...
Cached Biology News:Leeds research points to new therapy for hepatitis C treatment 2DOE Joint Genome Institute completes soybean genome 2DOE Joint Genome Institute completes soybean genome 3Oil spray reduces greenhouse gas emissions from pig finishing barns 2
... Optimization Kits without ammonium sulfate are compatible ... such as Taq and AmpliThem™™ DNA polymerases. ... PCR systems in one experiment by adding ... into the PreMixes supplied with the kit. ...
Special grade: for molecular biology Density: 1.000 g/mL (20 C)...
Matrix for protein MALDI-MS...
... IPL-41 is part of a series of media ... by Weiss et al. for the large scale ... The medium is primarily used for the growth ... and the propagation of viruses in these cell ...
Biology Products: